Investor Relations

Stock Reports
Yahoo Financial
CNN Money

See GeNOsys SEC Filings
Securities & Exchange Commission

GeNOsys Files Annual Report

GeNOsys filed its Annual Report (Form 10-K) today with the Securities and Exchange Commission for the fiscal year ended November 30, 2009.

The Annual Report can be reviewed on the SEC website at

www.sec.gov/Archives/edgar/data/1145328/000101041210000038/f10k2009fnl2.htm

March 1, 2010

GeNOsys Announces Production of Generators

Press Release Source: GeNOsys, Inc. On Thursday January 21, 2010, 11:54 am EST

PROVO, Utah–(BUSINESS WIRE)–GeNOsys, Inc. (OTCBB: GNYS- News) today announced the building of the first group of production nitric oxide gas generators. It is anticipated that the generators will be assembled and tested over the next few weeks. The Company plans to place this initial group of generators in research laboratories to facilitate the research of nitric oxide gas in the treatment of a number of conditions and diseases, research that has been very difficult due to the current high cost of nitric oxide gas.

“We are looking forward to placing these units in service in the near future to enable an acceleration of medical research utilizing nitric oxide gas,” stated Mr. John W.R. Miller, Chairman of the Board. “Making available systems that will generate nitric oxide gas, on demand and at an affordable cost, will be a valuable tool to researchers.”

About GeNOsys:

GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company’s Website at: www.genosysusa.com.

This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.

January 21, 2010

Shareholder Letter September 8, 2008

Dear GeNOsys Shareholders,

I would like to take this opportunity to update you on the Company’s progress since our previous shareholder letter of 18, March, 2008. Since that point, we have made tremendous strides toward completing our mission of developing on-site generation and delivery of medical grade Nitric Oxide gas. The Company is focused on its product line of portable and inexpensive Nitric Oxide (N0) gas generators for the control and treatment of tuberculosis and other human disease. The following letter will help you understand the Company’s timeline (including where we are as of today and the regulatory process), exactly what Nitric Oxide does, and why it is important in the fight of Tuberculosis, how our new patented technology compares to the current expensive old technology, and the market potential for Nitric Oxide (N0) gas generators. I hope, from this letter, you better understand how important it is to provide the medical community with a better and more affordable way to deliver medical grade Nitric Oxide gas. The world needs it and we expect our shareholders to benefit from this important development.

Best regards,

Clark Mower

GeNOsys Chairman of the Board of Directors

(All Attachments to this letter can be found in this PDF download. GeNOsys Shareholder Letter Q4 2008) (more…)

September 10, 2008

Quarterly Report

Item 2. Management’s Discussion and Analysis or Plan of Operation

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the consolidated financial statements included in our Form 10-KSB for the year ended November 28, 2006, and notes thereto.

(more…)